The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size was valued at US$ 4472.3 million in 2023. With growing demand in downstream market, the Liposomal and Lipid Nanoparticle Drug Delivery Systems is forecast to a readjusted size of US$ 8924.6 million by 2030 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market. Liposomal and Lipid Nanoparticle Drug Delivery Systems are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Liposomal and Lipid Nanoparticle Drug Delivery Systems. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Liposomal and Lipid Nanoparticle Drug Delivery Systems market.
Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer鈥揃ioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.
Key Features:
The report on Liposomal and Lipid Nanoparticle Drug Delivery Systems market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Liposomal and Lipid Nanoparticle Drug Delivery Systems market. It may include historical data, market segmentation by Type (e.g., Liposomes Drugs, Lipid Nanoparticle Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Liposomal and Lipid Nanoparticle Drug Delivery Systems market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Liposomal and Lipid Nanoparticle Drug Delivery Systems market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Liposomal and Lipid Nanoparticle Drug Delivery Systems industry. This include advancements in Liposomal and Lipid Nanoparticle Drug Delivery Systems technology, Liposomal and Lipid Nanoparticle Drug Delivery Systems new entrants, Liposomal and Lipid Nanoparticle Drug Delivery Systems new investment, and other innovations that are shaping the future of Liposomal and Lipid Nanoparticle Drug Delivery Systems.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Liposomal and Lipid Nanoparticle Drug Delivery Systems market. It includes factors influencing customer ' purchasing decisions, preferences for Liposomal and Lipid Nanoparticle Drug Delivery Systems product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Liposomal and Lipid Nanoparticle Drug Delivery Systems market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Liposomal and Lipid Nanoparticle Drug Delivery Systems market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Liposomal and Lipid Nanoparticle Drug Delivery Systems market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Liposomal and Lipid Nanoparticle Drug Delivery Systems industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Liposomal and Lipid Nanoparticle Drug Delivery Systems market.
Market Segmentation:
Liposomal and Lipid Nanoparticle Drug Delivery Systems market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segmentation by application
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size 2019-2030
2.1.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Type
2.2.1 Liposomes Drugs
2.2.2 Lipid Nanoparticle Drugs
2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type
2.3.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Market Share by Type (2019-2024)
2.4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application
2.5.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Market Share by Application (2019-2024)
3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Player
3.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Market Share by Players
3.1.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Players (2019-2024)
3.1.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2019-2024)
3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Liposomal and Lipid Nanoparticle Drug Delivery Systems by Regions
4.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Regions (2019-2024)
4.2 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth (2019-2024)
4.3 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth (2019-2024)
4.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth (2019-2024)
4.5 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth (2019-2024)
5 Americas
5.1 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2019-2024)
5.2 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2019-2024)
5.3 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2019-2024)
6.2 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2019-2024)
6.3 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems by Country (2019-2024)
7.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2019-2024)
7.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems by Region (2019-2024)
8.2 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2019-2024)
8.3 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Regions (2025-2030)
10.1.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Regions (2025-2030)
10.1.2 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast
10.1.3 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast
10.1.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast
10.1.5 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast
10.2 Americas Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Country (2025-2030)
10.2.1 United States Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.2.2 Canada Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.2.3 Mexico Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.2.4 Brazil Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3 APAC Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Region (2025-2030)
10.3.1 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3.2 Japan Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3.3 Korea Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3.4 Southeast Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3.5 India Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.3.6 Australia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Country (2025-2030)
10.4.1 Germany Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.4.2 France Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.4.3 UK Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.4.4 Italy Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.4.5 Russia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.5 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Region (2025-2030)
10.5.1 Egypt Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.5.2 South Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.5.3 Israel Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.5.4 Turkey Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.5.5 GCC Countries Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Forecast
10.6 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Type (2025-2030)
10.7 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.1.3 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Information
11.2.2 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.2.3 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Sun Pharmaceutical Main Business Overview
11.2.5 Sun Pharmaceutical Latest Developments
11.3 CSPC
11.3.1 CSPC Company Information
11.3.2 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.3.3 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 CSPC Main Business Overview
11.3.5 CSPC Latest Developments
11.4 Kinyond
11.4.1 Kinyond Company Information
11.4.2 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.4.3 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Kinyond Main Business Overview
11.4.5 Kinyond Latest Developments
11.5 Teva
11.5.1 Teva Company Information
11.5.2 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.5.3 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Teva Main Business Overview
11.5.5 Teva Latest Developments
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Information
11.6.2 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.6.3 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Fudan-Zhangjiang Main Business Overview
11.6.5 Fudan-Zhangjiang Latest Developments
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Information
11.7.2 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.7.3 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Zydus Cadila Main Business Overview
11.7.5 Zydus Cadila Latest Developments
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Information
11.8.2 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.8.3 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 TTY Biopharma Main Business Overview
11.8.5 TTY Biopharma Latest Developments
11.9 Pacira
11.9.1 Pacira Company Information
11.9.2 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.9.3 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Pacira Main Business Overview
11.9.5 Pacira Latest Developments
11.10 Luye Pharma
11.10.1 Luye Pharma Company Information
11.10.2 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.10.3 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Luye Pharma Main Business Overview
11.10.5 Luye Pharma Latest Developments
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Information
11.11.2 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.11.3 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Leadiant Biosciences Main Business Overview
11.11.5 Leadiant Biosciences Latest Developments
11.12 Ipsen
11.12.1 Ipsen Company Information
11.12.2 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.12.3 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Ipsen Main Business Overview
11.12.5 Ipsen Latest Developments
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Information
11.13.2 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.13.3 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Sayre Therapeutics Main Business Overview
11.13.5 Sayre Therapeutics Latest Developments
11.14 Jazz
11.14.1 Jazz Company Information
11.14.2 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.14.3 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Jazz Main Business Overview
11.14.5 Jazz Latest Developments
11.15 Alnylam
11.15.1 Alnylam Company Information
11.15.2 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.15.3 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Alnylam Main Business Overview
11.15.5 Alnylam Latest Developments
11.16 Bausch Health
11.16.1 Bausch Health Company Information
11.16.2 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.16.3 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Bausch Health Main Business Overview
11.16.5 Bausch Health Latest Developments
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Information
11.17.2 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.17.3 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Acrotech Biopharma Main Business Overview
11.17.5 Acrotech Biopharma Latest Developments
11.18 Takeda
11.18.1 Takeda Company Information
11.18.2 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.18.3 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Takeda Main Business Overview
11.18.5 Takeda Latest Developments
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Information
11.19.2 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.19.3 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Chiesi Farmaceutici Main Business Overview
11.19.5 Chiesi Farmaceutici Latest Developments
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Information
11.20.2 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Offered
11.20.3 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Gilead Sciences Main Business Overview
11.20.5 Gilead Sciences Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
